The stratification of patients for treatment of prostate cancer is based on very general parameters like prostate-specific antigen, Gleason score, and TNM classification.
We use these rough parameters for selection of active surveillance, active treatment, and even for the treatment selection in metastasized or castration-resistant prostate cancers. Up to now, we have not used individualized genetic classifiers for detailed sub-stratification, thus treating all patients as equal, and being only moderately successful. With the expected increase in systemic treatments, there is an apparent need for such classifiers. We will address these needs in this short commentary.
Written by:
Sedelaar JP, Schalken JA. Are you the author?
Radboud University Medical Center, Nijmegen, The Netherlands. ;
Reference: BMC Med. 2015 May 9;13:109.
doi: 10.1186/s12916-015-0344-1
PubMed Abstract
PMID: 25956920